LANCASTER, CA, January 18, 2012 – Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today reported financial results for its first quarter of fiscal year 2012 ended November 30, 2011 (1QFY12). Results below are reported for continuing operations (without the discontinued operations of the Company’s former Words+ subsidiary), except as noted.

1QFY12 highlights compared with 1QFY11:

  • Net sales increased 9.6% to first-quarter record $2.248 million from $2.050 million
  • Gross profit increased 11.7% to $1.896 million from $1.697 million
  • SG&A increased 2.0% to $0.700 million from $0.686 million, but decreased as a percent of revenues to 31.1% from 33.5%
  • R&D expenditures increased 14.9% to $454,000 from $395,000
  • Income before taxes increased 27.6% to $1.064 million from $0.834 million
  • Net income from continuing operations increased 30.9% to $755,000 from $577,000, and including the proceeds from the sale of Words+, partially offset by the discontinued operations of Words+, net income increased 71.1% to $971,000 from $567,000
  • Total diluted earnings per share, including discontinued operations, increased 100% to $0.06 from $0.03
  • Diluted earnings per share for only the continuing operations up 67% to $0.05 from $0.03

Ms. Momoko Beran, chief financial officer of Simulations Plus, said: “This was a very busy quarter, with increased Selling, General and Administrative expenses related to the attempted acquisition of assets of Entelos in bankruptcy court as well as the sale of our former Words+ subsidiary. Despite these nonrecurring expenses, we’re pleased to report these results that show continued strong top- and bottom-line performance, including record first-quarter revenue and a 30.9% increase in net income. Cash at the end of 1QFY12 was up 42.7% to $12.662 million compared to $8.873 million at the end of 1QFY11, and up 26.1% from $10.037 million at the beginning of the quarter. Shareholders’ equity increased 20.9% to $15.088 million compared to $12.482 million in 1QFY11.”

Walt Woltosz, chairman and chief executive officer of Simulations Plus, added: “Simulations Plus continues to demonstrate sustained strong growth in sales and even stronger sustained growth in net income. The increased sales and net income from our continuing operations for this new record first quarter are enhanced even more with the small profit from the sale of our former Words+ subsidiary. Accomplishing that sale was a major effort over the past half year that leaves us now with a focused business and without the losses that occurred all too often in the subsidiary that reduced the overall financial performance of the company. It’s worthy to note that as we compare this first quarter with last year, we had about $67,000 in grant revenues last year that we did not have this year, so comparing software and consulting revenue growth alone increased by about 13.4% rather than the 9.6% shown above. Our cash position is stronger than ever, and the board of directors is evaluating the potential effects of either another share repurchase program, an ongoing dividend with an attractive yield, or some combination of the two that could be accomplished without using all of our positive cash flow so that net cash would not decrease. Of course, there can be no assurances that the board will approve a share repurchase or dividend, but the board is committed to creating shareholder value.”

Woltosz continued: “We continue to evaluate acquisition opportunities as we can identify any that would fit our business model. The difficulty we’ve had in finding appropriate acquisition opportunities, i.e., those that would not require an inordinate amount of time and money to realize a reasonable return on investment, is a matter of record. We continue to grow organically and to pursue our aggressive marketing and sales program, which has yielded the growth that can be seen in this report. We are also making progress on our NCE (new chemical entity) project for malaria, with compounds in synthesis, and we expect to have samples ready for testing in the coming quarter.”

The Company has announced an investor conference call that will be webcast live at 1:15 PST/4:15 PM EST today, Wednesday, January 18, 2012, which may be accessed by first registering at the following website: https://www2.gotomeeting.com/register/267646562. Upon registering, you will receive a confirmation e-mail with a unique link and instructions for joining the call. Please dial in five to ten minutes prior to the scheduled start time. For listen-only mode, you may dial (314) 627-1519, and enter access code 367-620-098.


About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation and modeling software, which is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide. We also provide a productivity tool called Abbreviate! for PCs as well as an educational software series for science students in middle and high schools known as FutureLab. Simulations Plus, Inc., is headquartered in Southern California and trades on the NASDAQ Capital Market under the symbol “SLP.” For more information, visit our Web site at www.simulations-plus.com.


Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the Securities and Exchange Commission.



Simulations Plus, Inc. Condensed Balance Sheets

At November 30,2011 (Unaudited) and August 31, 2011 (Audited)

ASSETS

November 30,

August 31,

2011

2011

Current assets

Cash and cash equivalents

$ 12,662,240

$ 10,037,891

Income tax refund receivable

259,434

259,434

Accounts receivable, net of allowance for doubtful accounts of $0

1,203,863

1,170,861

Contracts receivable

219,683

185,816

Prepaid expenses and other current assets

106,783

123,954

Deferred income taxes

134,196

302,076

Current assets of discontinued operations

-

1,194,795

Total current assets

14,586,199

13,274,827

Long-term assets

Capitalized computer software development costs,

net of accumulated amortization of $4,573,869 and $4,416,669

2,233,674

2,188,982

Property and equipment, net

120,491

43,010

Customer relationships, net of accumulated amortization of $127,169 and $126,172

873

1,870

Other assets

18,445

18,445

Non-current assets of discontinued operations

-

340,204

Total assets

$ 16,959,682

$ 15,867,338

LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities

Accounts payable

$ 314,424

$ 176,136

Accrued payroll and other expenses

303,425

276,327

Accrued bonuses to officer

44,950

-

Accrued income taxes

328,900

168,897

Deferred revenue

108,482

141,191

Current liabilities of discontinued operations

-

378,567

Total current liabilities

1,100,181

1,141,118

Long-term liabilities

Deferred income taxes

771,726

656,047

Non-current liabilities of discontinued operations

-

33,558

Total liabilities

1,871,907

1,830,723

Commitments and contingencies

Shareholders' equity

Preferred stock, $0.001 par value

10,000,000 shares authorized

no shares issued and outstanding

-

-

Common stock, $0.001 par value

50,000,000 shares authorized

15,572,943 and 15,572,943 shares issued and outstanding

4,044

4,044

Additional paid-in capital

4,247,789

4,167,650

Retained earnings

10,835,942

9,864,921

Total shareholders' equity

15,087,775

14,036,615

Total liabilities and shareholders' equity

$ 16,959,682

$ 15,867,338



For further information:
Simulations Plus, Inc.
42505 10th Street West
Lancaster, CA
93534-7059 USA
www.simulations-plus.com
CONTACT: investor relations:
Contact: Renee Bouche